Biogen
Biogen’s diroximel fumarate impresses at Phase 3 in relapsing multiple sclerosis
May 31, 2019Medical Communications, Research and Development Biogen, diroximel fumarate, multiple sclerosis, pharma, relapsingg multiple sclerosis
New data for Biogen’s investigational therapy diroximel fumarate has been revealed at the Consortium of Multiple Sclerosis Centers (CMSC) in …
NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza
May 15, 2019Research and Development Biogen, NHS England, Spinraza, UK, pharma, sma, spinal muscular atrophy
NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza. England’s National Health …
Top Ten most popular articles on Pharmafile.com this week!
March 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz
This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …
Biogen and Eisai discontinue Phase 3 Alzheimer’s trial
March 21, 2019Research and Development Alzheimer's, Biogen, CNS, Eisai, mental health
Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of …
Top Ten most popular articles on Pharmafile.com this week!
March 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Gilead, HIV, Novartis, Scott Gottlieb, top 10
HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ …
Biogen boosts ophthalmology portfolio with $800m acquisition of gene therapy firm Nightstar
March 4, 2019Sales and Marketing Biogen, Nightstar, acquisition, pharma
Biogen has announced it has inked an agreement to acquire clinical-stage gene therapy firm Nightstar for a total value of …
UCB and Biogen’s lupus drug falls short at Phase 2b
October 24, 2018Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure
The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …
Samsung and Bioepis launch third Humira biosimilar in Europe
October 17, 2018Research and Development, Sales and Marketing Amgen, Biogen, Humira, Imraldi, Samusng Bioepis, pharma
Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of …
MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar
October 8, 2018Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis
American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …
UK Health Secretary Matt Hancock rallies against ‘rip off’ pharma companies
September 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Matt Hancock, NICE, Vertex, pharma, pricing
British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business …
NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay
August 14, 2018Manufacturing and Production, Sales and Marketing Biogen, NICE, Spinraza, UK, pharma, spinal muscular dystrophy
UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available …
PTC Therapeutics’ results in SMA has Biogen nervous
June 19, 2018Manufacturing and Production, Research and Development Biogen, PTC Therapeutics, biotech, drugs, pharma, pharmaceutical
Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that …
Biogen boosts pipeline with $1bn Ionis deal
April 23, 2018Sales and Marketing Biogen, Ionis, Spinraza, biotech, drugs, pharma, pharmaceutical
Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …
Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar
April 6, 2018Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma
Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …
Pfizer begins sell-off, shedding CNS drug to Biogen for $590m
March 13, 2018Manufacturing and Production, Sales and Marketing Biogen, CNS, Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer’s decision to back out of the neuroscience space was a strategic move that send shudders through the entire industry, …
